产品名称3D组织器官芯片模型,SynBBB血脑屏障模型,Idealized Co-Culture Network Chips,Idealized Co-Culture Network Chips (IMN2 TEER),Idealized Co-Culture Network Chips (IMN2 Linear)
品牌synvivo
产品货号3D组织器官芯片模型,SynBBB血脑屏障模型,Idealized Co-Culture Network Chips,Idealized Co-Culture Network Chips (IMN2 TEER),Idealized Co-Culture Network Chips (IMN2 Linear)
产品价格现货询价
联系人李先生
联系电话18618101725
产品说明

3D组织器官芯片模型

SynBBB血脑屏障模型,SynTumor 3D肿瘤模型,SynTox 3D毒理模型,SynRAM 3D炎症模型,synvivo血管模型芯片,SynALI气液界面肺模型

二、SynBBB血脑屏障模型

SynBBB血脑屏障模型通过复制脑组织细胞的组织学切片来重建体内微环境。该模型能够通过与跨血脑屏障(BBB)的内皮细胞进行通讯来实现此目的。结果,在SynBBB模型中,使用生理流体流很容易实现剪切诱导的内皮细胞紧密连接。这是其他模型(例如Transwell®模型)无法实现的。紧密连接变化的形成可以使用SynVivo细胞阻抗分析仪通过生化或电气分析(评估电阻变化)进行测量。在SynBBB分析中,很容易看到大脑组织细胞与内皮细胞之间的相互作用。 Transwell®模型不允许实时显示这些细胞之间的相互作用,这对于理解BBB微环境至关重要。

用于开发BBB模型的设备的示意图。 顶腔(外通道)用于培养血管(内皮细胞),而基底外侧腔(中央腔)用于培养脑组织细胞(星形细胞,周细胞或神经元)。 多孔结构使血管细胞与组织细胞之间可以进行通讯。 外通道宽度(OC),行进宽度(T),狭缝间距(SS),狭缝宽度(WS)。
重点包括:
准确的体内血液动力学切应力
实时可视化和定量细胞和屏障功能
大大减少了成本和时间
稳健易用的协议

产品购买选项
芯片:根据您的特定研究应用,您可以从基本的IMN2(径向或线性)或IMN2径向“ TEER兼容”芯片配置中进行选择。

试剂盒:运行SynBBB分析所需的所有基本组件都可以以试剂盒形式购买。提供两种套件格式,您可以在IMN2径向,IMN2线性或IMN2径向TEER芯片之间进行选择。

入门套件:首次购买时请选择

10个SynBBB芯片(选择IMN2径向,IMN2线性或IMN2径向TEER共培养芯片)
配件,包括油管,夹具,针头和注射器
气动灌注装置(灌注管路以除去空气时需要)
电池阻抗分析仪*(SynBBB TEER测量必需)
*仅包含在IMN2-TEER入门套件中
检测试剂盒:如果您以前购买过气动灌注设备,请选择此试剂盒格式

10个SynBBB芯片(选择IMN2径向,IMN2线性或IMN2径向TEER共培养芯片)
配件,包括油管,夹具,针头和注射器

SynVivo平台用于在芯片上创建个新生儿血脑屏障
天普大学的研究人员在芯片上使用SynBBB大脑对新生儿血脑屏障(BBB)的属性和功能进行建模。 SynBBB模型紧密模拟了体内的微环境,包括微流控芯片上的三维形态,细胞相互作用和流动特性。这项工作标志着个动态体外新生儿BBB模型,该模型提供适合于BBB功能研究和新型疗法筛选的实时可视化和分析。

新型动态新生儿血脑屏障芯片。
作者:S。Deosarkar,B。Prabhakarpandian,B。Wang,J.B。Sheffield,B。Krynska和M. Kiani。
一号,2015,DOI:10.1371 / journal.pone.0142725

SynBBB模型包括并排放置的组织隔室和血管通道,并由工程多孔屏障隔开。因此,研究人员能够在体内观察到的生理条件下共同培养新生大鼠脑内皮细胞和大鼠星形胶质细胞。内皮细胞形成完整的内腔并表现出紧密的连接形成,在与星形胶质细胞共培养下增加。发现芯片上的血脑屏障中的小分子渗透性与体内观察非常吻合。与Transwell模型相比,SynBBB的屏障功能显着改善,并且非常接近体内BBB的渗透性。


BBB-permeability
SynBBB and Transwell BBB were constructed with neonatal RBEC in the presence of ACM. Permeability of 40 kDa dextran in SynBBB is significantly lower than transwell but not significantly different from that of in vivo BBB in neonatal rats.
astrocyte-communication
Astrocyte and rat brain endothelial cell interaction at the porous interface between vascular channel and the tissue compartment

SynVivo Platform Used to Develop Blood Tumor Barrier On-A-Chip

Permeability Across a Novel Microfluidic Blood-Tumor-Barrier Model 
Authors: Tori B. Terrell-Hall, Amanda G. Ammer , Jessica I. G. Griffith and Paul R. Lockman
Fluids and Barriers of the CNS (2017) 14:3

In this study, Dr. Lockman’s team adapted the SynVivo BBB model to develop and characterize a BTB model. Results from the study demonstrate that the in vitro BTB model mimics the in vivo BTB with regard to permeability and efflux properties. In addition, inhibitor-based modulation of the permeability was readily quantified and compared very well with in vivo observations. According to Dr. Lockman “While some in vitro models have a flow component, this assay is the first-ever blood-tumor barrier developed using a commercially available microfluidic model with shear stress similar to that observed in vivo in addition to real-time visualization and quantitation.” This Blood Tumor Barrier model lays the foundation for use in screening assays for drug discovery and understanding of Central Nervous System diseases.

diffusion charts
diffusion charts
Representative brightfield image of Rhodamine 123 dye accumulation in the central compartment after 90 min of perfusion in the BBB model without an inhibitor (a) and with an inhibitor (b). Rate of fluorescent dye accumulation of Rho123 into central compartment after 90 min of dye perfusion in BBB, and BTB chips (c). Rate of fluorescent dye accumulation in BBB (d) and BTB (e) chips perfused with Rho123 ± P-gp inhibitors (Cyclosporine A or Verapamil). Statistical significance was determined using one-way ANOVA followed by Tukey’s multiple comparison tests, and student’s t test; *p < 0.05 significance between tracer and unrestricted diffusion kin, n = 3–4; +p < 0.05 significance between BBB/BTB models and the addition of inhibitor, n = 3–6. All data represent mean ± SEM. White rectangle scale bars 500 μm

SynBBB Blood Tumor Barrier On-A-Chip Advances Understanding of Therapeutic Transfer Across the Blood-Brain Barrier

Trastuzumab Distribution in an In-Vivo and In-Vitro Model of Brain Metastases of Breast Cancer
Authors:
 Tori B. Terrell-Hall, Mohamed Ismail Nounou, Fatema El-Amrawy, Jessica I.G. Griffith and Paul R. Lockman
Oncotarget. 2017; 8:83734-83744

Researcher Paul Lockman and colleagues at West Virginia University, report on one of the first studies to monitor and quantify Trastuzumab (Herceptin®) movement across the blood-brain barrier using the SynVivo Blood-Brain Barrier (BBB) on-a-chip. Trastuzumab is a monoclonal antibody that is a widely used therapeutic for the treatment of HER2+ breast cancer. In the study published in Oncotarget titled “Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer”, SynVivo’s BBB model was adapted to develop a blood tumor barrier (BTB) model. The model was comprised of HER2+ breast cancer cells followed by real-time monitoring of the tissue distribution of the antibody trastuzumab. Data showed that the permeability of trastuzumab in-vivo increased from the BBB to the BTB similar to that observed in the SynVivo model.

According to Dr. Lockman, “Development of an in vitro model with the ability to predict in vivo responses across the BBB is critical to progress our understanding and therapeutic strategies for brain disorders”. SynVivo’s in vivo validated microfluidic 3D tissue models provide a valuable resource for augmenting translational research for drug discovery and delivery.

diffusion charts
Mechanism of trastuzumab movement. Linear central compartment accumulation of t-Rho123 in in-vitro BBB and BTB microfluidic chip models. Representative image of model with TRITC labeled t-Rho123 flowing over HUVEC cells in the outer compartment and either astrocytes or JIMT-1 cancer cells in the central compartment (A). Rate of t-Rho123 movement in each model plotted against the unrestricted diffusion kin; ** p<0.0033 significance between BBB model and unrestricted diffusion kin, n=3; *** p<0.0005 significance between BTB model and unrestricted diffusion kin, n=3. All data represent mean ± S.E.M. Each model is significantly different than 0 (p < 0.05) (B). Representative graphs of the rate of accumulation of t-Rho123 in the BBB (C) and BTB

SynBBB Blood-Brain Barrier On-A-Chip Assay Used For Screening of Novel Therapeutics in Real-Time

Protein Kinase C-Delta Inhibition Protects Blood-Brain Barrier from Sepsis-Induced Vascular Damage
Authors: Yuan Tang, Fariborz Soroush, Shuang Sun, Elisabetta Liverani, Jordan C. Langston, Qingliang Yang, Laurie E. Kilpatrick, and Mohammad F. Kiani. J
Neuroinflammation. 15: 309 (2018).

This publication reports on the use of the blood-brain barrier model to elucidate the regulation and relative contribution of Protein Kinase C-delta in the control of individual steps in neuroinflammation during sepsis. The role of PKC-delta-TAT peptide inhibitor as a potential therapeutic for the prevention or reduction of cerebrovascular injury in sepsis-induced vascular damage was also studied.

Vascular integrity was assessed using the SynBBB Co-Culture model with primary human brain microvascular endothelial cells and Astrocytes. Endothelial cell permeability, TEER, and neutrophil transmigration were directly evaluated. SynBBB also allowed for real-time monitoring of neutrophil-endothelial interaction under physiologically relevant flow conditions.

SYNBBB_permeability

PKCδ activation is a key signaling event that alters the structural and functional integrity of BBB leading to vascular damage and inflammation-induced tissue damage. PKCδ-TAT peptide inhibitor has therapeutic potential for the prevention or reduction of cerebrovascular injury in sepsis-induced vascular damage.

Human Blood-Brain Barrier on a Chip Developed with hCMEC/D3 Brain Endothelial Cell Line and Primary Human Astrocytes

A Microfluidic Model of Human Brain (uHuB) for Assessment of Blood-Brain Barrier
Authors: Tyler D. Brown, Maksymillian Nowak, Alexandra V. Bayles, Balabhaskar Prabhakarpandian, Pankaj Karande, Joerg Lahann, Matthew Helgeson, Samir Mitragotri.
Bioengineering and Translational Medicine. 15: 309 (2019; 4:e10126)

hCMEC/D3 cell line forms a complete lumen underflow and displays the appropriate tight junction markers.

(a–f) Confocal images of hCMEC/D3 monolayers in the μHuB after conditioning to flow stained with ActinRed? 555 ReadyProbes? (actin, red) and Hoechst 33342 (nucleus, blue). (a) Onwardlooking view of μHuB device consisting of two vascular (apical) compartments lined with hCMEC/D3 monolayers. (b) Crosssectional view of hCMEC/D3 monolayers in μHuB forming a complete inner lumen approximately 200?μm (width) by 100?μm (height). (c) Onwardlooking view of one quadrant of the μHuB model as outlined in yellow in (a). (d) Lower half of (c), lined with a complete hCMEC/D3 monolayer. (e) Crosssectional view of inner lumen. (f) Same crosssection as (e) at 90° viewing angle
uhub model

Co-Culture of hCMEC/D3 and Primary Astrocytes in the Human SynBBB Blood-Brain Barrier On-A-Chip

hCMEC/D3 monolayers (green) were cultured in the vascular (apical) compartments with primary human astrocytes (red) in the tissue (basolateral) compartment (nuclei, blue). (a) Onward‐looking view of complete, three‐dimensional reconstruction of the co culture SynBBB model. (b) Zoomed‐in yellow region of (a) with arrows pointing to regions where astrocyte end‐feet are protruding to hCMEC/D3 monolayer. (scale bar for b?=?20?μm